No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
AXNX240517P67500
- 0.25
- -0.55-68.75%
15min DelayClose May 10 16:00 ET
0.50High0.25Low
0.50Open0.80Pre Close11 Volume1 Open Interest67.50Strike Price300.00Turnover7.18%IV-0.27%PremiumMay 17, 2024Expiry Date0.07Intrinsic Value100Multiplier5DDays to Expiry0.18Time Value100Contract SizeAmericanOptions Type-0.5196Delta0.6957Gamma269.72Leverage Ratio-0.0184Theta-0.0041Rho-140.14Eff Leverage0.0327Vega
Intraday
- 5D
- 1D
News
Express News | Needham Reiterates Hold on Axonics
Axonics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/06/2024 — Needham Reiterates → Hold 02/29/2024 5.62% RBC Capital → $71 Reiterates Sector Perform → Sec
Analysts Offer Insights on Healthcare Companies: Lineage Therap (LCTX), Axonics Modulation Technologies (AXNX) and Artivion (AORT)
Analysts Offer Insights on Healthcare Companies: 10x Genomics (TXG), Axonics Modulation Technologies (AXNX) and Eli Lilly & Co (LLY)
Axonics Q1 EPS $(0.38) Misses $(0.08) Estimate, Sales $91.41M Beat $89.59M Estimate
Axonics (NASDAQ:AXNX) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.08) by 375 percent. This is a 100 percent decrease over losses of $(0.19) per sh
Earnings Flash (AXNX) AXONICS Reports Q1 Revenue $91.4M
04:03 PM EDT, 04/30/2024 (MT Newswires) -- Earnings Flash (AXNX) AXONICS Reports Q1 Revenue $91.4M
Comments
Analysts' consensus shows Axonics performing as expected, with no major estimate changes post recent results. Despite a predicted slowdown in revenue growth, Axonics is still expected to outpace the wider industry.
Analysts Have Made A Financial Statement On Axonics, Inc.'s (NASDAQ:AXNX) Full-Year Report 1
Axonics' consistent revenue growth, despite last year's lack of profit, has led to a 33% annual increase in share price over the past five years, making it a potential investment opportunity.
Meghan Scanlon from Boston Scientific forecasts merger to enhance support for urologists handling chronic conditions. Acquisition may improve earnings per share over time, though GAAP earnings may see lesser increase due to related expenses.
Investors believe in Axonics' potential for future revenue growth, supporting higher stock prices despite a high P/S ratio. They discount the chance of a revenue decrease, but risks and other factors must also be considered.
Axonics' strong revenue growth may be driving its stock performance and could be attractive for growth investors. The recent sell-off may open up investment opportunities if long-term growth signs are positive.
Read more